Skip to main content
. Author manuscript; available in PMC: 2018 Feb 23.
Published in final edited form as: Lancet HIV. 2016 May 27;3(9):e410–e420. doi: 10.1016/S2352-3018(16)30016-9

Figure 1. Trial profile.

Figure 1

Study participants could have more than one reason for exclusion. Integrase inhibitor regimen was elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate and protease inhibitor based regimen was ritonavir-boosted atazanavir with emtricitabine and tenofovir disoproxil fumarate.